Research & Development
Seres Therapeutics Names Shaff as President, Chief Executive Officer
16 January 2019 - - US-based microbiome therapeutics platform company Seres Therapeutics, Inc. (NASDAQ: MCRB) has appointed Eric D. Shaff as president and chief executive officer, the company said.

Shaff, who is currently chief operating and Financial officer, succeeds Roger J. Pomerantz, M.D. Shaff has also joined Seres' board of directors and will continue to serve as Seres' principal financial officer on an interim basis.

Pomerantz will continue as chairman of Seres' board of directors.

Shaff has served as Seres' chief financial officer, executive vice president and treasurer since November 2014, and in January 2018, he was appointed to the additional role of chief operating officer.

He also serves on the board of directors for Sigilon Therapeutics and has extensive experience in the biotechnology field, having worked at Momenta Pharmaceuticals and Genzyme Corp., where he was vice president of Finance for the Personalized Genetic Health division.

Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.

The company's lead programme, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the US Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection.

SER-287 is currently being evaluated in a Phase 2B study in patients with active mild-to-moderate ulcerative colitis.

Seres is advancing SER-401 to augment the efficacy of immuno-oncology treatment.

In addition, the company has several other microbiome therapeutic candidates in preclinical development for various serious diseases.
Login
Username:

Password: